Update to ACC/AHA Heart Failure Performance Measures; Quadruple Therapy and HF; ACEi, ARBs, and Chronic Kidney Disease

Dr. Eagle, a renowned expert in cardiology, shares fresh insights on heart failure management. He delves into the 2024 updates to clinical performance measures, emphasizing new metrics aimed at improving patient care. The conversation shifts to the promising benefits of rapidly starting quadruple therapy for newly diagnosed heart failure. Dr. Eagle also reviews clinical trials on the effectiveness of ACE inhibitors and ARBs for patients with advanced chronic kidney disease, highlighting important implications for treatment strategies.